ArticleWorld journal of surgical oncology2026
Residual tumor deposits after neoadjuvant therapy and 3-year survival outcomes in gastric cancer: a single-center retrospective cohort study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe prognostic relevance of residual tumor deposits after neoadjuvant therapy (ypTD) in gastric cancer remains insufficiently defined. This study evaluated associations between ypTD positivity and 3-year disease-free survival (DFS) and overall survival (OS) after curative-intent gastrectomy.
methodsThis single-center retrospective cohort study included 336 patients with locally advanced, clinically lymph node-positive gastric adenocarcinoma who underwent neoadjuvant therapy followed by R0 gastrectomy. Patients were classified by postoperative ypTD status. Survival analyses were restricted to the postoperative 36-month observation window. Kaplan-Meier analysis, log-rank tests, Cox models, exploratory ypN-stratified analyses, and within-cohort model performance comparisons were performed.
resultsFifty-one patients (15.2%) were ypTD-positive. ypTD-positive patients had higher proportions of ypT3-4 disease, ypN2-3 disease, and lymphovascular invasion. The 3-year DFS rate was lower in the ypTD-positive group than in the ypTD-negative group (41.2% vs. 69.8%; log-rank P < 0.001), whereas 3-year OS did not differ significantly (68.6% vs. 77.9%; P = 0.063). In the fully adjusted model, ypTD positivity was associated with increased DFS event risk (HR 1.79, 95% CI 1.08-2.95; P = 0.023), but not OS (HR 0.87, 95% CI 0.46-1.65; P = 0.676). Adding ypTD increased the 36-month time-dependent AUC from 0.598 to 0.645 in within-cohort exploratory comparisons.
conclusionsypTD positivity was associated with an increased risk of DFS events within 36 months after surgery, whereas no statistically significant association with OS was observed. ypTD may provide potential supplementary prognostic information for recurrence-risk assessment; however, its biological interpretation, potential clinical applicability, and long-term prognostic value require validation in larger multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.